Liver Diseases  >>  simtuzumab (GS 6624)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
simtuzumab (GS 6624) / Gilead
NCT01672866 / 2012-002488-88: Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Terminated
2b
222
Canada, US, Europe
Placebo, SIM, GS-6624
Gilead Sciences
Liver Fibrosis Due to NASH
08/16
12/16
NCT01672879 / 2012-002489-11: Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

Terminated
2b
259
Canada, US, Europe
Placebo, SIM, GS-6624
Gilead Sciences
Liver Fibrosis Due to NASH
09/16
01/17

Download Options